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Non communicable diseases (NCDs) are a major cause of morbidity and mortality worldwide, 
accounting for approximately 70% of global deaths.1 The United Nations’ Sustainable Development 
Goals (SDG) Target 3.4 aims to reduce the risk of premature mortality from NCDs by one third by 2030. 
Chronic respiratory diseases (CRDs) are common and frequently neglected NCDs that span the life 
course, affecting children, adolescents and adults. They are associated with high levels of morbidity 
and risk of mortality due to  frequent symptoms, activity limitation, and intermittent exacerbations or 
‘attacks’  requiring acute care. CRDs disproportionately affect the poor and those in low- and middle-
income countries (LMICs) where there often few resources available to prevent or manage them.2  
 
This review focuses on asthma, COPD, bronchiectasis and post-TB lung disease in LMICs. We discuss 
the early life origins of many of these conditions, difficulties in diagnosis and management in LMICs, 
research priorities, broader health system challenges, and strategies for research and clinical 
capability strengthening for CRD care in LMICs. We propose pathways to solutions that would 
contribute to achieving the SDGs for health including reducing premature mortality from NCDs and 
helping to achieve Universal Health Coverage (UHC).  
 
 
2. EARLY LIFE ORIGINS OF CHRONIC RESPIRATORY DISEASE 
Evidence from high income countries (HICs) indicates that the in utero environment is crucial for lung 
development, and that lung function at pre-school age predicts lung function in early adulthood and 
beyond, into at least the seventh decade of life.3 4 Early data from the Drakenstein child health study 
in South Africa – one of the first birth cohorts in the sub-Saharan African setting – confirm that the 
same is true in LMICs, with lung function tracking from birth through to the preschool years.5 Common 
to both settings, but more prevalent and severe in LMICs, are in utero and early childhood exposures 
related to maternal illness and social deprivation, environmental exposures including indoor and 
outdoor pollution, malnutrition, and a high burden of respiratory and systemic infections. All of these 
may inhibit lung development such that individuals fail to reach an optimal peak in early adulthood, 
and increase the risk of CRDs later in life. The high burden of detrimental early life exposures in LMICs 
may explain the lower lung volumes observed amongst asymptomatic non-smoking adults in many 
sub-Saharan African settings, compared to age- and height-matched adults in HICs.6 This finding in 
LMICs is of concern because reduced forced expiratory volumes in 1-second (FEV1) and forced vital 
capacity (FVC) in adulthood have been associated with cardiovascular and metabolic morbidity, as 
well as differences in mortality both within and between populations.4 7 8  
 
In-utero exposures 
Tobacco and air pollution: In utero exposure to nicotine is thought to alter lung structure and function, 
and immune responses in the developing foetus. Analysis of exposure and outcome data for 675 infant 
and mother pairs within the Drakenstein cohort found that one third of mothers smoked during 
pregnancy, with lower tidal volumes and higher lung clearance indices at age 6 weeks (implying 
impaired lung and airway development) observed in infants of smoking women compared with non-
smoking women.9 Similar outcomes have been seen in relation to other forms of air pollution 
exposure.10 
Social deprivation: Maternal stress, adverse living conditions, and intimate partner and 
neighbourhood violence are all too common in LMICs.11 Maternal psychological distress is associated 
with measures of neonatal health including weight for age and head circumference,11 but has not been 
shown to directly predict child lung function. Maternal alcohol exposure during pregnancy adversely 
impacts lung function at 6-weeks, but this effect is no longer seen by one-year.5 9 
HIV infection: Maternal HIV prevalence remains high in many LMICs but the introduction of ‘test and 
treat’ approaches to antiretroviral treatment with programmes to prevent maternal to child 
transmission have dramatically decreased rates of perinatal infection. Whilst HIV-exposed but 
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uninfected infants may have reduced early lung function, by age two years residual impairment is seen 
only in those children whose mothers had poorly controlled HIV disease during pregnancy.12  
 
Childhood exposures 
Acute lower respiratory infection: Early childhood bacterial and viral infections are common in LMICs 
and are both a consequence of poor general health and associated with ongoing respiratory illness. 
Respiratory syncytial virus (RSV), rhinovirus (RV), adenovirus and Influenza A are amongst the most 
common pathogens detected in children with acute respiratory illnesses in LMICs.13 14 Data from HICs 
indicate that wheezing illnesses associated with RV and RSV in early life are strong predictors of 
childhood asthma by 6-years of age,15 whilst lower respiratory tract infection (LRTI) associated with 
adenovirus has been associated with obliterative bronchiolitis/bronchiectasis in sub-Saharan African 
countries. Pneumonia (incidence ~0.2-0.3 episodes/child year) is a major cause of mortality in 
children,16 and LRTIs in early childhood are an independent risk factor for reduced lung function by 1-
year.9 It remains unclear whether such early life respiratory infections are manifestations of 
predisposition to chronic lung disease or independent causes of later disease.  
Pulmonary tuberculosis: Children <15 years account for 11% of incident TB cases globally,17 and 
paediatricians in LMICs routinely report seeing a high burden of post-TB sequelae including bronchial 
stenosis, bronchiectasis, and lung destruction.  
Chronic HIV infection: Large numbers of children previously infected with vertically-acquired HIV are 
now growing into adolescence.18 These long-term survivors experience a high burden of CRDs 
including bronchiectasis, and bronchiolitis obliterans.18 19   
Malnutrition: LMICs increasingly face a dual burden of maternal and childhood malnutrition, which 
results in foetal growth restriction, stunting, wasting, and isolated nutrient deficiencies, but also 
children who are overweight or obese.20  Limited data are available suggesting in utero and early 
childhood starvation has adverse effects on lung development that persist into adult life. Obesity is 
also thought to cause long term airway disease. 21  
Environmental exposures: The relationship between early childhood biomass fuel exposure and lung 
development remains unclear: delayed introduction of clean burning stoves into Guatemalan 
households (at child age 18-57-months vs <6m) was associated with lower, but not statistically 
significant, rates of lung growth,22 and data from a clean stoves intervention study in rural Malawi 
showed a small but statistically significant difference (0.2 z-scores) in the FVC of children from 
households who had previously been provided with a clean burning stove compared to those who had 
not.23  
 
Meeting the challenge 
Most predictors of poor lung development in utero and early childhood are amenable to public health 
interventions, particularly interventions on smoking cessation, alcohol reduction and improved 
nutrition in women of childbearing age. These interventions should include both health promotion 
and political action such as taxation and regulation of advertising through effective legislation. The 
latter may be particularly relevant in the context of rapid development and increasing marketing and 
interference by tobacco, alcohol and food and beverage companies in LMICs, with limited national 
regulatory frameworks.2 Programmes that support HIV infected mothers to prevent perinatal 
transmission, and the provision of early childhood HIV testing must be maintained. Maternal 
education about childhood nutrition and vaccination is important. Lastly, the socioeconomic 
environment is a key determinant of respiratory and general health. Efforts to alleviate poverty among 
mothers and children will be paramount for improving respiratory and other childhood outcomes.  
 
ASTHMA  
Asthma is the most common chronic respiratory disease globally, affecting more than 350 million 
people in 2015,24 with extremely high rates of asthma-related deaths in LMICs compared with HICs. 
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This is likely related to lack of access and underutilisation of effective treatments for prevention of 
acute attacks, in particular inhaled corticosteroids.    
 
Diagnosis 
The Global Initiative for Asthma (GINA) indicates a syndromic approach for asthma diagnosis in LMICs, 
but stresses the importance of measuring variability in airflow for confirmation, using peak flow 
monitoring or spirometry with reversibility testing.25 However, access to these tools remains limited 
in LMICs, such that diagnostic capacity is severely constrained.26   
 
Management 
Inhaled corticosteroids (ICS) improve the control of asthma symptoms, and prevent exacerbations and 
deaths in people with asthma.27 However, ICS are frequently underutilised by people with asthma in 
LMICs owing to their cost or non-availability. Instead there is over-reliance on relievers such as inhaled 
bronchodilators, oral preparations of salbutamol and theophylline.28 29 Long-term follow-up with up-
titration of medication for symptom control remains limited, with 52-76% loss to follow-up seen 
within 1-year in pilot projects in China, Benin and Sudan.29 28 As-required use of inhalers combining 
ICS with the rapid-onset bronchodilator formoterol is now recommended by the Global Initiative for 
Asthma (GINA) for adolescents and adults at treatment steps 1 and 2.25 31 This is based on recent large 
clinical trials which show that this approach is equivalent or superior to use of regular ICS with as-
needed short-acting ß2 agonists (SABA) for reducing the risk of severe exacerbations, with a much 
lower dose of ICS but no clinically important difference in symptom control.32-35 Likewise, in moderate-
severe asthma, maintenance and reliever therapy with combination ICS-formoterol reduces severe 
exacerbations compared with conventional ICS-LABA therapy with SABA reliever. In mild asthma, if 
combined ICS-rapid-onset-bronchodilator preparations are not available or affordable in LMICs, ICS 
should be used whenever a SABA is taken.  
 
Meeting the challenge 
Global guidelines for asthma care in LMICs are available and must be adapted and adopted for national 
use in LMICs, with guidance for standardised decentralised care by a variety of levels of health care 
workers; doctors, nurses and health extension. Implementation requires health worker training to 
recognise clinical presentations of asthma (syndromic diagnosis), and improved access to diagnostic 
tools (peak flow meters and spirometry), and quality-assured essential asthma medicines. The 
inclusion of budesonide-formoterol on the WHO Essential Medicines list that may be used as 
controller and reliver, may facilitate this if made more widely available.36  Education of both patients 
and providers will be required to ensure appropriate prescription and use of inhalers, with emphasis 
on the use of ICS  and training in inhaler technique. In the acute setting, use of pressurized metered 
dose inhalers (pMDI) with or without spacers, which are as effective as nebulisers, may demonstrate 
the effectiveness of inhalers for symptom relief and encourage ongoing use. Health services with 
capacity for follow-up for patients with this chronic disease is rare in LMIC, but essential for preventing 
over-reliance on emergency services, and improving long-term symptom control and maintenance of 
productive lives for patients. 
 
COPD 
The global burden of COPD is heterogeneous, with widespread variability in the prevalence, causes, 
clinical presentation and mortality reported between and within LMICs. This is compounded by 
controversy over how to define abnormal spirometry results (e.g. whether percent predicted or lower 
limit of normal (LLN) boundaries should be used to identify abnormal results, and which reference 
ranges to use for standardisation of measurements) and whether to consider all patients with fixed 
airflow limitation as having COPD.6 Community-based data indicate that the prevalence of airway 
obstruction is between 6–20% in Latin America,37-39 and 5–24% in SSA.40-43 It is thought that LMICs 
contribute to 76.5% of the global COPD burden, 85% of global COPD deaths and 85% of the global 
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COPD disability adjusted life years (DALYs).24 Tobacco smoking remains the dominant risk factor for 




High rates of underdiagnosis and misdiagnosis have been observed globally: in the PLATINO study 
these were 89% and 77%,48 and data from a primary care population in Latin America indicate rates 
of 77% and 30.4%. 49 Combined analysis of data from national and international COPD surveys 
indicates that over 80% of COPD cases identified on spirometry remain undiagnosed within routine 
clinical care.50 Perhaps unsurprisingly those with mild disease and without a history of exacerbations 
or admissions are less likely to have a diagnosis, but race, educational status, and lack of contact with 
health services also emerge as risk factors for underdiagnosis, suggesting broader socioeconomic 
determinants also.49 50 As noted above, global access to spirometry is limited, and given this is the 
crucial diagnostic test for COPD, this is likely a key constraint.  
 
Management 
Gold standard management of smoking-related COPD includes non-pharmacological interventions 
(supported smoking cessation, pneumococcal and influenza vaccination, and pulmonary 
rehabilitation) and pharmacological treatment with inhaled therapies (SABA and long-acting ß2 
agonists (LABA), long-acting muscarinic antagonists (LAMA), and ICS) according to the severity of 
disease. These interventions are largely under-utilised in LMICs. In Latin America, population based 
surveys indicate that only half of smokers had physician counselling, a quarter received any respiratory 
medication, and influenza vaccination was scarce.51 52 Results from the PUMA study showed that in 
primary care, the most widely used inhaled therapy was short-acting bronchodilator with long-acting 
bronchodilators and ICS relatively less used.53 There are no clinical trials that have investigated the 
appropriate pharmacotherapy for non-smoker COPD in LMICs, which may differ from that required by 
those with smoking-related COPD.  
 
Meeting the challenge 
Many of the challenges around the diagnosis and management of COPD are similar to those outlined 
for asthma, including better access to spirometry and inhaled therapies (long-acting bronchodilators), 
education for both patients and health care providers, access to long term follow-up care, and use of 
approved standardized guidelines. Lack of access to spirometry  has been shown to be the strongest 
predictor for an incorrect diagnosis of COPD in LMICs.55 Broader access to cost-effective non-
pharmacological interventions including smoking cessation and pulmonary rehabilitation are also 
needed. Controversies about the interpretation of spirometry in LMICs must be resolved – 
classification systems must be validated against long-term patient outcomes, in order to ensure that 
treatment efforts are focused on groups with genuine pathology who are most likely to benefit from 
active management. Lastly, in the presence of limited resources, a better understanding of how to 
prevent, diagnose and treat COPD in LMICs is paramount.57 Smoking remains the key driver of COPD 
globally, and lessons learnt in HICs about public health and policy approaches to regulation must be 
urgently translated across to LMICs. However, more data on the risks, nature, outcomes and 




The reported population prevalence of non-cystic fibrosis bronchiectasis in HICs has increased in 
recent years to 566/100,000,58 with disease prevalence and severity associated with older-age and 
female-gender. Evidence on the epidemiology of bronchiectasis in LMICs is however lacking,59 perhaps 
because bronchiectasis is defined by the presence of abnormal dilatation and distortion of airways 
seen on computerised-tomography (CT) imaging which is a technology not widely available in resource 
6 
 
poor settings. However, it appears that the prevalence, aetiology, and risk for bronchiectasis may be 
markedly different in LMICs, with more post-infectious disease, a higher burden of more severe 
disease in younger adults, and differences in colonising / infecting microbiology.58 60 61 
 
Diagnosis 
Diagnosis of bronchiectasis in LMICs remains challenging. The clinical presentation is with chronic 
cough and sputum production in adults, and ‘failure to thrive’ in children with chronic respiratory 
symptoms and recurrent infections. However, ‘gold standard’ diagnosis of bronchiectasis requires CT 
imaging, but its presence may be surmised when chest X-ray features are extensive; ring shadows, 
fluid filled saccules and tramlining. To our knowledge there are no guidelines for syndromic diagnosis 
of bronchiectasis in LMICs, nor evidence of the sensitivity / specificity of chest x-ray changes alone.  
 
Management 
Management of bronchiectasis in HICs is increasingly individualised and focused on addressing 
‘treatable traits’ with the use of airway clearance tools, vaccination to prevent infection, appropriate 
treatment of infecting or colonising organisms, and early diagnosis and active management of 
intercurrent fungal, and non-tuberculous mycobacterial (NTM) disease.62 These individualised 
approaches are not widely available in LMICs, and there is need for developing feasible and scalable 
programmatic approaches and treatment guidelines for bronchiectasis in LMICs. 58 In many LMICs this 
may form part of the TB programme, which may be the commonest cause of bronchiectasis. Vigilance 
for recurrences of active pulmonary TB must be maintained. 
 
Meeting the challenge 
Education of health workers about bronchiectasis as a cause of chronic cough is required. Use of 
patient-centred, low cost tools such as airway clearance have been shown to be acceptable and 
effective in children in South Africa, and should be optimised for use in LMICs. More affordable 
diagnostic approaches suitable for LMICs should be developed, although CT imaging is becoming more 
widely available. Important research questions include understanding the microbiology of 
bronchiectasis in LMICs in both children and adults to inform population-level antibiotic 
recommendations. More epidemiological data on the burden and risk factors for bronchiectasis in 
LMICs are needed, and would be facilitated by inclusion of LMIC data in bronchiectasis registries; this  
would also further facilitate the inclusion of research priorities for bronchiectasis in LMICs in 
international consensus documents.  
 
POST TB LUNG DISEASE  (PTLD) 
Pulmonary tuberculosis (pTB) survivors, estimated at 58 million in this century alone,17 have two-to-
four-fold odds of persistently abnormal spirometry in adulthood (airway obstruction and low FVC 
patterns) compared to TB-naïve groups, with bronchiectasis, parenchymal cavitation and destruction, 
and fibrotic change seen on imaging.63-66 Mortality in adult survivors of TB is almost three-times that 
in healthy controls and the excess is frequently due to non-respiratory causes67; however, the direct 
association between PTLD and mortality remains unclear. Of the 10 million annual cases of incident 




Post TB lung diseases are heterogenous and include both structural and physiological lung 
abnormalities. Diagnosis can be made from spirometry or chest x-ray imaging, but these tests are not 
routinely performed at successful TB treatment completion. Thus, the majority of patients with PTLD 
are therefore discharged without ongoing care. Persons who have previously been treated for pTB are 
at increased risk of recurrence, whether re-activation or re-infection. TB diagnostics may have limited 
specificity in this group,68-70 and those with PTLD have a high risk of unnecessary retreatment, with its 
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attendant risk of side-adverse.71 and there are no guidelines available for the diagnosis of underlying 
PTLD or active management to prevent ongoing clinical decline.  
 
Management 
There are no evidence-based guidelines for the diagnosis and management of PTLD,72 or on the 
rational use of TB diagnostics to identify recurrent disease in this group. TB treatment guidelines pay 
little attention on long-term morbidity, and health systems remain poorly equipped to provide 
ongoing care.73 Current guidance for PTLD management in LMICs is based on approaches developed 
and used for COPD and bronchiectasis; education about avoiding cannabis and smoking which are 
common co-exposures in the TB population, remaining physically active, using airway clearance tools, 
vaccinations as per national guidelines, and use of inhaled bronchodilators for airflow obstruction.74 
The use of ICS in PTLD is not recommended as their use has been shown to increase the risk of both 
lower respiratory tract infections, including of mycobacteria other than tuberculosis, and recurrence 
of pTB-disease. Pulmonary rehabilitation may improve patient quality of life. 75 
 
Meeting the challenge 
PTLD is associated with a single clearly defined exposure, and there is therefore an opportunity to 
identify those with disease at TB-treatment completion. Evidence is required to inform decisions 
about how this is should be done, which patients would benefit from ongoing follow-up, and the 
impact and cost-efficacy of clinical interventions for this group, before screening for PTLD is 
implemented in LMICs. In addition, the broader cardiovascular, psychological and socioeconomic 
morbidities faced by TB-survivors must also be addressed within any packages of post-TB care,76 as 
well as improved approaches to the diagnosis of recurrent TB disease. 
 
HEALTH SYSTEMS STRENGTHENING 
Strong health systems which are capable of providing effective and efficient services across the care 
continuum will be key to the provision of NCD care in LMICs. Development of these will require 
attention to the 6 key ‘building blocks’ specified by the World Health Organization (WHO), including: 
(i) service delivery, (ii) health workforce, (iii) health information systems, (iv) access to essential 
medicines, (v) financing, and (vi) leadership/governance.77 Several key weaknesses have been 
identified in these areas, with respect to respiratory care in LMICs. Health system surveillance data 
for respiratory diseases other than TB remain sparse,78 limiting the capacity of countries to identify 
and plan for the health care needs of their populations. Guidelines for the management of CRDs 
remain limited, and were identified in only 64% of countries in the 7th NCD country capacity survey 
2019.79 Crucially, the health workforce remains poorly equipped to deliver respiratory care, with 
numbers of respiratory specialists remaining low,80-82 and most care delivered at the primary care level 
often by nursing staff.83 Access to key diagnostic tools including spirometry and imaging is limited and 
in 2019 peak flow / spirometry were available in 45% of primary care facilities only, compared to 88% 
for blood glucose measurement.79 Solutions to some of these challenges are explored below. 
 
Integrated delivery of CRD care 
Front-line primary-care staff in LMICs have a broad remit and are expected to provide preventative 
and curative care, for infectious and non-infectious diseases, to both children and adults. As such, it is 
crucial that CRD services are not siloed, but rather are efficiently integrated within broader services, 
and targeted to local needs. Several approaches to integrated care have been developed for use in 
LMICs.84 85 Early models, such as the WHO Practical Approach to Lung Disease (PAL),86 which was 
developed, in part, to improve case finding for TB, focussed only on respiratory diseases. These have 
been followed by tools with more comprehensive scope including the Package of Care Kit (PACK) for 
children, adolescents and adults.87 PACK was developed in Cape Town and is now in use in South 
Africa,88 Brazil,89 Nigeria,90 and other countries (www.knowledgetranslation.co.za). It includes a 
decision support tool for use across a range of clinical presentations and is available in both paper and 
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electronic tablet form. It integrates local management guidelines and evidence, and is updated almost 
annually to allow for this, and is supported by a continuous programme of on-site, case-based, 
interactive training.91 92 Although not specifically focused on CRDs, qualitative data confirm the 
effectiveness of this integrated care approach in improving CRD services, including the treatment of 
asthma, diagnosis of tuberculosis and appropriate referral to hospital.91-93  
 
We indicate that respiratory and tuberculosis services should be closely linked in LMICs. Patients with 
CRDs frequently present with chronic or worsening respiratory symptoms and in high TB incidence 
settings will usually require investigation for active TB disease. However, if TB investigations are 
negative it is important that alternative respiratory diagnoses are considered. Similarly, patients with 
PTLD at TB-treatment completion would benefit from clear and efficient integrated care pathways. 
 
Lastly, NCD programmes in LMICs must be encouraged to incorporate palliative care support within 
their services. This is particularly important for CRDs which are frequently irreversible, progressive, 
and can be associated with distressing symptoms such as severe breathlessness in advanced stages. 
Integration of palliative care into CRD services will require cultural awareness, education of staff and 
patients, development of symptom management algorithms, and access to opioid medications.94  
 
Improving access to diagnostic tools 
Specific challenges to accessing diagnostic tools, including spirometry and imaging, at the primary care 
level include the funding of these services, access to robust biomedical engineering  support for 
maintenance, 95 and training in how to perform diagnostic tests, maintain quality control, and 
accurately interpret results. Some of these barriers will be lessened in the coming years, with advances 
in the development of robust portable spirometry equipment, and increasing investment in portable 
CXR for community-based TB diagnostics. However, education about the importance of equipment 
maintenance, and quality assurance of testing will be needed to deliver investigations such as 
spirometry in resource-constrained settings.96 It is likely that more complex respiratory diagnostics 
such as CT imaging, full lung function testing, and bronchoscopy remain the purview of tertiary centres 
in LMICs, but these diagnostics are of value in the training and retention of specialist physicians and 
research capacity, and so limited investment in their centralised use may be of some benefit.  
 
Improving access to treatment 
Although many key respiratory medications are included in the WHO essential medications list (Table 
1),97 access remains limited: in 2019, ICS were generally available in 19% of low-income countries 
compared to 96% of high-income countries, and the figures were 55% and 100% for bronchodilators. 
Even where available, respiratory medications were frequently not provided free of charge to 
patients, such that in LMICs they frequently remain inaccessible. For respiratory diseases, non-
pharmacological interventions are also crucial. Pulmonary Rehabilitation (PR) and smoking cessation 
are among the most cost-effective interventions for chronic respiratory disease, and can be 
successfully adapted for delivery in LMICs, 75 98 but access remains limited. This is in part due to lack 
of awareness, but also limited support to modify these tools for local use, and to embed them within 
clinical care. Advocacy around access to both pharmacological and non-pharmacological interventions 
will be required if CRD outcomes are to be improved. 
 
 
RESEARCH PRIORITIES & RESEARCH CAPACITY STRENGTHENING 
This review has highlighted several areas of uncertainty which suggest research priorities to improve 
the management of CRDs in LMICs (Table 2). However, these cannot be addressed without a thriving 
critical mass of LMIC investigators. The ‘Structured Operational Research Training Initiative’ (SORT-IT) 
course, and the American Thoracic Society/Pan African Thoracic Society ‘Methods in Epidemiological, 
Clinical and Operational Research’ (PATS-MECOR) course are two respiratory focused training 
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programmes that provide training and networking opportunities for research-interested clinicians 
from LMICs, in order to build this capacity. Both SORT-IT and PATS-MECOR focus on clinical, 
epidemiological and operational research, or the “science of doing better”.99 100 They also both offer 
three modules that cover topics including concept development, grant and protocol writing, quality 
assured data capture and analysis, and manuscript writing. Participants are required to achieve 
various targets in order to progress, and strong, hands-on mentorship is offered throughout. Together, 
these courses have trained over 1000 participants from 90 countries, resulting in a large body of 
published literature that has been shown to contribute to changes in policy and practice.101 102-105 
Graduates have a strong track record of remaining in research after course completion,106-109 or 




CRDs contribute substantially to the burden of disease in LMICs. Achieving the SDGs will require action 
to address this burden of disease through better prevention and care. The major determinants of CRD 
in LMICs that are amenable to intervention are: 1) poor maternal nutrition and health; 2) exposure to 
airborne contaminants (tobacco smoke, air pollution and occupational exposure to dust and fumes); 
and 3) severe or untreated respiratory infections including tuberculosis. Policy action directed at these 
causes of CRD will yield benefits in the short- and long-term. However, a substantial burden of disease 
will continue to exist and therapeutic strategies are required to mitigate suffering from 
breathlessness, cough, sputum production and activity limitation and to reduce the risk of severe 
attacks that impede the ability to work or study, require urgent medical care and may cause death. 
The UHC agenda should be co-opted and adapted to the needs of those suffering from CRD to ensure 
that they get affordable and sustained access to appropriate and effective diagnostic evaluation and 
to therapeutic interventions, both pharmacological and non-pharmacological. The balance between 
programmatic approaches attempting to deliver simple standardised interventions, and personalised 
approaches seeking to target interventions more precisely, needs careful consideration and should be 
tailored to the local health care setting. However, in all settings, this likely to require resourcing and 
capacity building at the most peripheral level of the healthcare system. This will be a challenge for 
many LMICs but highlights the importance of health system strengthening, capacity building and 
implementation research in realising the potential of UHC to reduce the burden of CRD. 
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Table 1: Essential medicines for CRD management97 
Category Drug  
Respiratory medications Beclomethasone 
Budesonide 
Budesonide + Formoterol 
Epinephrine (adrenaline) 
Ipratropium bromide 
Salbutamol – inhaled & nebulised 
Tiotropium 
Antiallergics and medicines used in anaphylaxis Prednisolone 
Medical gases Oxygen 
Medicines for pain and palliative care Opioid preparations (codeine, fentanyl, morphine) 
Vaccines Influenza vaccine (seasonal) 






Table 2: Suggested research and clinical care priorities, for the delivery of CRD care in LMICs 
 
Remit Research need 




Birth cohorts in diverse settings in LMICs, to obtain prospective data on how genetic parameters, 
and in utero & early childhood exposures effect lung development. 
Investigation of the long-term impact of LRTI or TB in children, and mechanisms for 
development of chronic respiratory disease 
Investigation of the origins, nature, and outcomes associated with low FVC phenomenon seen 
in LMICs 
Vaccines and new strategies to reduce childhood LRTI 
Asthma How can access to basic effective asthma care including access to affordable quality-assured 
SABA, ICS and ICS-formoterol be made available to everyone who needs it? 
Can the GINA-recommendation for as-required ICS-formoterol for steps 1 and 2 of asthma 
treatment be scaled-up in pragmatic way that accounts for difficulties in making a definitive 
diagnosis of asthma and the potential overlap with other diagnoses like COPD, TB and HIV? 
COPD Longitudinal data on patient-outcomes associated with airway obstruction in smokers and non-
smokers in LMICs 
Investigation of the efficacy of pharmacological and non-pharmacological therapies for non-
smoking related COPD in LMICs 
Bronchiectasis Data on the microbiology of bronchiectasis in LMICs, including colonising organisms, and those 
associated with exacerbations 
Investigation of the diagnosis and management of bronchiectasis in children in LMICs 
Post-TB lung disease Investigation of host, pathogen, and environmental risk factors for PTLD 
Longitudinal data on patient outcomes related to PTLD, including morbidity and mortality 
Investigation of the performance of TB diagnostic tools in those with PTLD being investigated 
for recurrent TB disease 
CRD diagnosis Consensus guidelines for the quality control of spirometry performed in routine clinical practice 
in LMICs settings 






Investigation of pathogens causing respiratory exacerbations of CRDs in LMICs, to inform 
antibiotic guidelines and vaccine use. 
Adaptation of non-pharmacological CRD management tools for use in LMICs, including 
pulmonary rehabilitation, airway clearance tools, and smoking cessation programmes. 
Investigation of effect of ICS on risk of TB disease, in high TB incidence settings 
Inclusion of LMICs in international CRD registries and consensus statements regarding global 
CRD research priorities 
Health systems 
  
Methods for programmatic data capture, to contribute data on the burden and nature of CRDs 
in LMICs, and to allow for local service planning 
Models of integrated CRD care in LMICs, which are: 
-         Co-developed with patients and responsive to patient needs 
-         Integrated with TB services 
-         Integrated with palliative care services 
With tools for the evaluation of clinical impact, and health system / patient costs. 
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